Impacts of tumor microenvironment during neoadjuvant chemotherapy in patients with esophageal squamous cell carcinoma

被引:2
|
作者
Sugawara, Kotaro [1 ]
Fukuda, Takashi [1 ]
Murakami, Chiaki [2 ,3 ]
Oka, Daiji [1 ]
Yoshii, Takako [4 ]
Amori, Gulanbar [2 ,5 ,6 ]
Ishibashi, Kumiko [2 ]
Kobayashi, Yasuhito [2 ]
Hara, Hiroki [4 ]
Kanda, Hiroaki [2 ]
Motoi, Noriko [2 ,7 ]
机构
[1] Saitama Canc Ctr, Dept Gastroenterol Surg, Saitama, Japan
[2] Saitama Canc Ctr, Dept Pathol, 780 Komuro, Ina, Saitama 3620806, Japan
[3] Saitama Med Univ, Saitama Med Ctr, Dept Pathol, Saitama, Japan
[4] Saitama Canc Ctr, Dept Gastroenterol, Saitama, Japan
[5] Japanese Fdn Canc Res, Canc Inst, Div Pathol, Tokyo, Japan
[6] Japanese Fdn Canc Res, Canc Inst Hosp JFCR, Dept Pathol, Tokyo, Japan
[7] Saitama Canc Ctr, Ctr Canc Genom Med, Saitama, Japan
关键词
esophageal squamous cell carcinoma; immune checkpoint inhibitor; neoadjuvant chemotherapy; surgery; tumor microenvironment; INFILTRATING LYMPHOCYTES; CANCER; EXPRESSION; SURVIVAL; THERAPY;
D O I
10.1111/cas.16203
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
With the advent of immune checkpoint inhibitors (ICIs), a better understanding of tumor microenvironment (TME) is becoming crucial in managing esophageal squamous cell carcinoma (ESCC) patients. We investigated the survival impact of TME status and changes in patients with ESCC who underwent neoadjuvant chemotherapy (NAC) followed by surgery (n = 264). We examined immunohistochemical status (CD4+, CD8+, CD20+, Foxp3+, HLA class-1+, CD204+, and programmed death ligand-1 [PD-L1+]) on 264 pre-NAC and 204 paired post-NAC specimens. Patients were classified by their pre- and post-NAC immune cell status and their changes following NAC. Our findings showed that pre-NAC TME status was not significantly associated with survival outcomes. In contrast, post-NAC TME status, such as low level of T cells, CD4+ T cells, and high PD-L1 combined positive score (CPS), were significantly associated with poor overall survival (OS). Notably, TME changes through NAC exerted significant survival impacts; patients with consistently low levels of T cells, low levels of CD4+ T cells, or high levels of PD-L1 (CPS) had very poor OS (3-year OS: 35.5%, 40.2%, and 33.3%, respectively). Tumor microenvironment changes of consistently low T cells, low CD4+ T cells, and high PD-L1 were independent predictors of poor OS in multivariate Cox hazards analyses, while factors indicating post-NAC status (T cells, CD4+, and PD-L1 [CPS]) alone were not. Therefore, we suggest that the consistently low T/high PD-L1 group could benefit from additional therapies, such as ICIs, and the importance of stratification by the TME, which has recently been recognized. Tumor microenvironment after neoadjuvant chemotherapy (NAC), such as low T cells, low CD4+ cells, or high programmed death ligand-1 [PD-L1], were significantly associated with poor survival in patients with esophageal squamous cell carcinoma. Importantly, immune cell changes following NAC, such as consistently low T cells, consistently low CD4+ cells, or persistently high PD-L1, were independent predictors for poor survival.image
引用
收藏
页码:2819 / 2830
页数:12
相关论文
共 50 条
  • [1] The Immunological Impact of Neoadjuvant Chemotherapy on the Tumor Microenvironment of Esophageal Squamous Cell Carcinoma
    Tsuchikawa, Takahiro
    Miyamoto, Masaki
    Yamamura, Yoshiyuki
    Shichinohe, Toshiaki
    Hirano, Satoshi
    Kondo, Satoshi
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (05) : 1713 - 1719
  • [2] The Immunological Impact of Neoadjuvant Chemotherapy on the Tumor Microenvironment of Esophageal Squamous Cell Carcinoma
    Takahiro Tsuchikawa
    Masaki Miyamoto MD
    Yoshiyuki Yamamura
    Toshiaki Shichinohe
    Satoshi Hirano
    Satoshi Kondo
    [J]. Annals of Surgical Oncology, 2012, 19 : 1713 - 1719
  • [3] Neoadjuvant chemotherapy enhances anti-tumor immune response of tumor microenvironment in human esophageal squamous cell carcinoma
    Okuda, Sho
    Ohuchida, Kenoki
    Nakamura, Shoichi
    Tsutsumi, Chikanori
    Hisano, Kyoko
    Mochida, Yuki
    Kawata, Jun
    Ohtsubo, Yoshiki
    Shinkawa, Tomohiko
    Iwamoto, Chika
    Torata, Nobuhiro
    Mizuuchi, Yusuke
    Shindo, Koji
    Moriyama, Taiki
    Nakata, Kohei
    Torisu, Takehiro
    Morisaki, Takashi
    Kitazono, Takanari
    Oda, Yoshinao
    Nakamura, Masafumi
    [J]. ISCIENCE, 2023, 26 (04)
  • [4] Response to neoadjuvant immune checkpoint inhibitors and chemotherapy in Chinese patients with esophageal squamous cell carcinoma: the role of tumor immune microenvironment
    Xiaoyuan Wang
    Xiaodong Ling
    Changhong Wang
    Jinfeng Zhang
    Yingnan Yang
    Hao Jiang
    Yanzhong Xin
    Luquan Zhang
    Hao Liang
    Chengyuan Fang
    Dayong Zheng
    Jinhong Zhu
    Jianqun Ma
    [J]. Cancer Immunology, Immunotherapy, 2023, 72 : 1619 - 1631
  • [5] Response to neoadjuvant immune checkpoint inhibitors and chemotherapy in Chinese patients with esophageal squamous cell carcinoma: the role of tumor immune microenvironment
    Wang, Xiaoyuan
    Ling, Xiaodong
    Wang, Changhong
    Zhang, Jinfeng
    Yang, Yingnan
    Jiang, Hao
    Xin, Yanzhong
    Zhang, Luquan
    Liang, Hao
    Fang, Chengyuan
    Zheng, Dayong
    Zhu, Jinhong
    Ma, Jianqun
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (06) : 1619 - 1631
  • [6] Impacts of Cigarette Smoking on the Tumor Immune Microenvironment in Esophageal Squamous Cell Carcinoma
    Wang, Geng
    Pan, Chuqing
    Cao, Kexin
    Zhang, Jingbing
    Geng, Hui
    Wu, Kusheng
    Wen, Jing
    Liu, Caixia
    [J]. JOURNAL OF CANCER, 2022, 13 (02): : 413 - 425
  • [7] Neoadjuvant Chemotherapy Versus Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma
    Nakashima, Yuichiro
    Saeki, Hiroshi
    Hu, Qingjiang
    Tsuda, Yasuo
    Hisamatsu, Yuichi
    Ando, Koji
    Oki, Eiji
    Maehara, Yoshihiko
    [J]. ANTICANCER RESEARCH, 2018, 38 (12) : 6809 - 6814
  • [8] Impact of neoadjuvant chemotherapy on tumor infiltrating dendritic cell in esophageal squamous cell carcinoma
    Nishimura, Junya
    Tanaka, Hiroaki
    Yamakoshi, Yoshihito
    Tamura, Tatsuro
    Toyokawa, Takahiro
    Muguruma, Kazuya
    Hirakawa, Kosei
    Ohira, Masaichi
    [J]. CANCER SCIENCE, 2018, 109 : 601 - 601
  • [9] Neoadjuvant Chemotherapy or Adjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma
    Sun, Hai-Bo
    Yan, Sen
    Liu, Xian-Ben
    Xing, Wen-Qun
    Chen, Pei-Nan
    Liu, Shi-Lei
    Li, Peng
    Ma, Ya-Xing
    Lerut, Toni
    Daoud, Ahmed
    Jiang, Duo
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (04) : 2443 - 2450
  • [10] Neoadjuvant Chemotherapy or Adjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma
    Sun, Hai-Bo
    Yan, Sen
    Liu, Xian-Ben
    Xing, Wen-Qun
    Chen, Pei-Nan
    Liu, Shi-Lei
    Li, Peng
    Ma, Ya-Xing
    Lerut, Toni
    Daoud, Ahmed
    Jiang, Duo
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (04) : 2443 - 2450